Monitor the Company's next periodic filing for any financial impact from the leadership transition and its stated pivot toward technology-driven businesses beyond medical cannabis.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
IM Cannabis Corp. appointed Ronen Zalayet as CEO and Ohad Melnik as independent director, succeeding Oren Shuster who resigned as CEO and director. The filing contains no financial results, guidance, or material operational data, it is a routine leadership and board transition.
Key Facts
- Ronen Zalayet appointed CEO effective November 19, 2026, succeeding Oren Shuster
- Oren Shuster resigned as CEO and director but remains a director of Israeli subsidiaries
- Ohad Melnik appointed independent director, subject to Israel Medical Cannabis Agency approval
- Shakked Shuster appointed CEO of Focus Medical Herbs Ltd., the Israeli subsidiary
- Resignation of Oren Shuster was not related to any disagreement with the Company
Financial Impact
No financial figures disclosed; market cap is $1M
Risk Factors
- Leadership transition may disrupt operations
- Company's liquidity position and going concern disclosure noted in forward-looking statements
- Nasdaq continued listing compliance risk mentioned
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-005308 |
| Document: zk2636456.htm | 0001178913-26-005308 |
| Document: 0001178913-26-005308-index-headers.html | 0001178913-26-005308 |
| Document: 0001178913-26-005308-index.html | 0001178913-26-005308 |
| Document: 0001178913-26-005308.txt | 0001178913-26-005308 |
| Earnings Context (Synthetic; results releases only) | 0001178913-26-005308 |
Track record
26 reports on IMCC
9 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +82.97% at T+60 after the Aug 13, 2026 report. 12 of 14 went positive at some point.
Filters
- Nov 20, 20261d ago 6-K Neutral 3/10 Viewing Entry $0.5100 settles Dec 21
- Nov 19, 20263d ago EFFECT Bearish 4/10 Entry $0.4662 settles Dec 18
- Nov 18, 20263d ago 6-K Bearish 5/10 Entry $0.4662 settles Dec 18
- Nov 17, 20264d ago SC 13G Neutral 4/10 Entry $0.4937 settles Dec 16
- Nov 13, 20268d ago 6-K Bearish 6/10 No price data
- Nov 13, 20268d ago Press Release Bearish 6/10 Entry $0.4950 settles Dec 15
- Nov 13, 20268d ago SC 13G/A Neutral 2/10 Entry $0.4950 settles Dec 15
- Nov 4, 202617d ago 6-K Bearish 6/10 Entry $0.5934 settles Dec 4
- Nov 4, 202617d ago Press Release Bearish 5/10 Entry $0.5934 settles Dec 4
- Oct 21, 20264w ago EFFECT Neutral 4/10 Entry $1.19 to $0.4937 ▼ −58.51% −52.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers